Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
A.G. Leventis Foundation - International
IKY_Greek State Scholarships Foundation - International
P. BROCA
research program ARISTEIA - International
ARISTEIA 39
research program ARISTEIA - International
European Union (European Social Fund, ESF) - International
Greek national funds through the Operational Program - International
MIS 5002514
Target Identification and Development of Novel Approaches for Health and Environmental Applications - International
NSRF 2014-2020
Competitiveness, Entrepreneurship and Innovation - International
Greece and the European Union (European Regional Development Fund) - International
PubMed
30851065
DOI
10.1002/humu.23728
Knihovny.cz E-zdroje
- Klíčová slova
- CHEK2 variants, breast cancer, functional assay, yeast,
- MeSH
- alely MeSH
- checkpoint kinasa 2 genetika metabolismus MeSH
- frekvence genu MeSH
- genetická predispozice k nemoci MeSH
- genetické asociační studie MeSH
- konformace proteinů MeSH
- lidé MeSH
- molekulární modely MeSH
- mutace * MeSH
- rodokmen MeSH
- Saccharomyces cerevisiae genetika metabolismus MeSH
- substituce aminokyselin MeSH
- výpočetní biologie metody MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- checkpoint kinasa 2 MeSH
- CHEK2 protein, human MeSH Prohlížeč
Genetic testing for cancer predisposition leads to the identification of a number of variants with uncertain significance. To some extent, variants of BRCA1/2 have been classified, in contrast to variants of other genes. CHEK2 is a typical example, in which a large number of variants of unknown clinical significance were identified and still remained unclassified. Herein, the CHEK2 variant assessment was performed through an in vivo, yeast-based, functional assay. In total, 120 germline CHEK2 missense variants, distributed along the protein sequence, and two large in-frame deletions were tested, originating from genetic test results in breast cancer families, or selected from the ClinVar database. Of these, 32 missense and two in-frame deletions behaved as non-functional, 73 as functional, and 15 as semi-functional, after comparing growth rates of each strain with positive and negative controls. The majority of non-functional variants were localized in the CHK2 kinase and forkhead-associated domains. In vivo results from the non-functional variants were in agreement with in silico predictions, and, where available, with strong breast cancer family history, to a great extent. The results of the largest, to date, yeast-based assay, evaluating CHEK2 variants, can complement and assist in the classification of rare CHEK2 variants with unclear clinical significance.
Citace poskytuje Crossref.org
CHEK2 Germline Variants in Cancer Predisposition: Stalemate Rather than Checkmate